What is the current ImmuPharma market capitalization?
The current market capitalization of ImmuPharma is 6.45 M GBP.
ImmuPharma Market capitalization 2024
ImmuPharma Market capitalization
6.45 M GBP
ImmuPharma Dividend yield
Ticker
IMM.L
ISIN
GB0033711010
WKN
A0BMC4
In 2024, ImmuPharma's market cap stood at 6.45 M GBP, a -34.16% increase from the 9.8 M GBP market cap in the previous year.
The ImmuPharma Market capitalization history
| YEAR | REVENUE (undefined GBP) | GROSS MARGIN (%) | NET INCOME (undefined GBP) |
|---|---|---|---|
| 2024e | 0.1 | 118,62 | - |
| 2023e | 0.11 | 108,98 | -13.06 |
| 2022 | - | - | -3.81 |
| 2021 | 0.12 | 99,70 | -8.17 |
| 2020 | 0.13 | 100,26 | -6.86 |
| 2019 | 0.08 | 151,42 | -6.12 |
| 2018 | 0.08 | 145,18 | -7.21 |
| 2017 | 0.15 | 78,43 | -6.22 |
| 2016 | 0.16 | 71,61 | -5.32 |
| 2015 | 0.08 | 154,43 | -3.9 |
| 2014 | 0.18 | 63,85 | -2.87 |
| 2013 | - | - | -3.69 |
| 2012 | - | - | -3.84 |
| 2011 | 0.02 | 590,00 | -3.36 |
| 2010 | 0.03 | 100,00 | -1.98 |
| 2009 | 22.05 | 81,18 | 8.1 |
| 2008 | 0.06 | 100,00 | 4.68 |
| 2007 | 0.06 | 196,67 | -3.08 |
| 2006 | 0.05 | 236,00 | -1.29 |
| 2005 | 0.03 | 393,33 | -2.48 |
ImmuPharma Aktienanalyse
What does ImmuPharma do?
ImmuPharma PLC is a biopharmaceutical company specializing in the development of drugs for the treatment of autoimmune diseases and cancer. The company was founded in 1999 and is headquartered in London, England. ImmuPharma's history began with the discovery of a new peptide extracted from the trail of a snail. This substance has potent immunomodulatory potential and can inhibit the growth of certain tumor cells. ImmuPharma recognized the potential of this discovery and began developing a new drug based on this peptide. ImmuPharma's business model is to develop innovative drugs and license or sell them to large pharmaceutical companies. The company works closely with leading scientists and experts in drug development to ensure the efficacy and safety of its products. ImmuPharma has focused on two main areas: autoimmune diseases and cancer. Autoimmune diseases are conditions in which the immune system malfunctions and attacks the body. The autoimmune diseases that ImmuPharma targets include lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and myasthenia gravis. ImmuPharma has also developed a drug called Lupuzor for the treatment of systemic lupus erythematosus (SLE). SLE is a severe autoimmune disease that causes inflammation and pain in various parts of the body. Lupuzor was developed as a first-in-class drug that regulates the immune system and reduces inflammation without compromising the body's normal defense function. In the field of cancer, ImmuPharma has also developed promising products that aim to inhibit tumor progression. The company has identified and tested a range of peptide- and protein-based drug candidates, including IPP-204106, which is used for the treatment of advanced prostate cancer. Last year, ImmuPharma also developed a new drug called Ureka for the treatment of urinary tract infections. Ureka is a bacterial toxin that specifically targets E. coli bacteria, which are the most common cause of urinary tract infections. In recent years, ImmuPharma has entered into several important partnerships to advance the development of its drugs. One partnership is with the Chinese company Avion Pharmaceuticals, which holds the marketing rights for Lupuzor in North America, Australia, and New Zealand. Another partnership is with the US company Orphan Reach, which supports the development and marketing of Ureka. Overall, ImmuPharma represents innovation and progress in drug development. The company is dedicated to a crucial purpose, seeking cures for those suffering from autoimmune diseases and cancer. Through a combination of scientific excellence and strategic partnerships, ImmuPharma has the potential to achieve significant therapeutic advancements and improve the lives of countless patients. ImmuPharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring ImmuPharma's Market Capitalization
ImmuPharma's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of ImmuPharma's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
ImmuPharma's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in ImmuPharma’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about ImmuPharma Stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like ImmuPharma.
How has the market capitalization of ImmuPharma developed in recent years?
The market capitalization of ImmuPharma has increased/decreased by -34.16% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of ImmuPharma?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of ImmuPharma?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of ImmuPharma have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does ImmuPharma pay?
Over the past 12 months, ImmuPharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmuPharma is expected to pay a dividend of 0 GBP.
What is the dividend yield of ImmuPharma?
The current dividend yield of ImmuPharma is .
When does ImmuPharma pay dividends?
ImmuPharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmuPharma?
ImmuPharma paid dividends every year for the past 0 years.
What is the dividend of ImmuPharma?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmuPharma located?
ImmuPharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmuPharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmuPharma from 5/30/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 5/30/2024.
When did ImmuPharma pay the last dividend?
The last dividend was paid out on 5/30/2024.
What was the dividend of ImmuPharma in the year 2023?
In the year 2023, ImmuPharma distributed 0 GBP as dividends.
In which currency does ImmuPharma pay out the dividend?
The dividends of ImmuPharma are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmuPharma
Our stock analysis for ImmuPharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuPharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
